Appointments (9446Z)

TIDMHIK

RNS Number : 9446Z

Hikma Pharmaceuticals Plc

24 January 2011

Hikma promotes Bassam Kanaan to President and Chief Operating Officer of MENA and Europe and Khalid Nabilsi to Chief Financial Officer

London, 24 January 2011 - Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK)("Hikma"), the fast growing multinational pharmaceutical group, is pleased to announce the following changes to the Group's organisational structure. These changes reflect the increasing scale and internationalisation of the Group and will support Hikma's continued growth.

Bassam Kanaan has been appointed President and Chief Operating Officer ("COO") for the MENA and EU regions, and he will relinquish his current role as Chief Financial Officer ("CFO"). Bassam joined Hikma as CFO in 2001, playing a leading role in the IPO in 2005. In February 2009, Bassam assumed responsibility for Operations, Manufacturing and Supply Chain Management in Europe and MENA.

Khalid Nabilsi, Corporate Vice President for Finance, has been appointed Chief Financial Officer. Khalid also joined Hikma in 2001 and was a member of the IPO team. Since then he has held several senior positions in the Finance department, including Group Financial Controller, and has been instrumental in the development of the Group Finance function.

Michael Raya, Corporate Vice President and CEO West-Ward, has been appointed Executive Vice President and CEO of USA. Mike successfully led the turnaround of Hikma's Generics business in 2008. In his new role he will have responsibility for all Group activities in the USA.

Riad Mishlawi, Vice President European Operations, has been appointed EU Vice President and Global Head of Injectables. Riad first joined Hikma's Injectables management team in the early 1990's and has played an important role in the development of this global business.

Commenting on the appointments, Said Darwazah said:

"As CFO, Bassam has made a significant contribution to the success and growth of the company. I am delighted he has accepted this new role, which reflects the progress he has driven since assuming his operations role in 2009. Khalid's strong knowledge of the Group and contributions as VP Finance mean he is well placed to assume this important role.

"Mike and Riad's appointments reflect the significant opportunities we see to grow both our US business and our global Injectables business.

"I am very pleased with the strength of our management team and the continuity in succession that we have been able to achieve, which puts us in a strong position to continue our growth going forward."

The changes are effective immediately.

-- ENDS --

Enquiries:

 
 Hikma Pharmaceuticals PLC 
 Susan Ringdal                                     +44 (0)207 399 
  Investor Relations Director                       2760 
 
 Financial Dynamics 
 Ben Atwell/Julia Phillips/Jonathan Birt/Matthew   +44 (0)20 7831 
  Cole                                              3113

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Branded", "Injectables" and "Generics", based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2009, Hikma achieved revenues of $637 million and profit attributable to shareholders of $78 million. For news and other information, please visit www.hikma.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCDKQDPOBKKDDB

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024